Loading clinical trials...

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM) | Clinical Trials | Clareo Health

RECRUITINGNA

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Randomised Controlled Trial Of Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

NCT07486401•National Healthcare Group Polyclinics

View on ClinicalTrials.gov

Summary

The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting. Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management

Eligibility

Age

21 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Singaporeans or Singapore Permanent Residents
•2. Patients aged ≥21 to 65 years old
•3. Physician diagnosed asthma for duration of at least 4 weeks
•4. On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment
•5. No asthma exacerbations\* in the preceding 4 weeks before randomisation
•6. Able and willing to attend study appointments approximately every 4-monthly over a 1-year period
•7. Able to provide informed consent
•8. Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) \*Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more days, emergency department visit, or hospitalization

Exclusion Criteria

•1. History of life-threatening asthma requiring intubation or intensive care unit admission
•2. Severe asthma or difficult to treat asthma
•3. Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids
•4. Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion
•5. Current use of beta-blocking agents including eye-drops
•6. Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment
•7. Known diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease or bronchiectasis
•8. Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study
•9. Current enrolment in other interventional clinical trial for asthma
•10. Female subjects who are pregnant or planning pregnancy during the study period
+2 more criteria

Locations (1)

National Healthcare Group Polyclinics

Singapore, Singapore

Key Dates

Start Date

December 3, 2025

Primary Completion Date

December 31, 2028

Completion Date

December 31, 2029

Last Updated

March 20, 2026

Enrollment

240

ESTIMATED participants

Conditions

Asthma ExacerbationsBiomarkers / BloodEosinophil Blood Count

Interventions

Biomarker-directed treatment for asthma management

DIAGNOSTIC_TEST

Usual Care

OTHER

Contacts

Wern Ee Tang

CONTACT

(65) 6355 3000 wern.ee.tang@nhghealth.com.sg

Individualizing Treatment for Asthma in Primary Care (Full Study)

NCT07052942

AsthmaAsthma Attack+1 more

View study

RECRUITINGPHASE2

Nitrous Oxide in the Treatment of Acute Suicidal Ideation

NCT06636357

SuicidalityEEG+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Blood Eosinophil Guided Versus Usual Care In The Management Of Mild To Moderate Asthma at Primary Care (BEAM)

Inclusion Criteria

Exclusion Criteria

Individualizing Treatment for Asthma in Primary Care (Full Study)

Nitrous Oxide in the Treatment of Acute Suicidal Ideation

A Cohort Study of Risk Factors and Prognosis for Frequent Acute Asthma Exacerbations Phenotype

Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients

Study on Effect of Papworth Technique in Anemic Asthmatic Pediatrics